Business Context and Reporting Period
Company: Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Scinai is a developmental-stage biopharmaceutical company with two business units: (1) an R&D unit developing nanosized VHH antibodies (NanoAbs) for inflammation and immunology, currently focused on an anti-IL-17 candidate for psoriasis; and (2) a Contract Development and Manufacturing Organization (CDMO) unit providing GMP manufacturing services. The company operates primarily in Israel and has recently established subsidiaries in the U.S. and Poland.
Key Financial Metrics
| Metric (in thousands USD) | 2024 | 2023 |
|---|---|---|
| Revenues | $658 | $0 |
| Cost of Revenues | $1,238 | $0 |
| Gross Loss | $(580) | $0 |
| Operating Expenses | $8,058 | $9,706 |
| Operating Loss | $(8,638) | $(9,706) |
| Gain on Troubled Debt Restructuring | $14,759 | $0 |
| Net Income (Loss) | $4,796 | $(6,500) |
| Cash and Cash Equivalents (Year End) | $1,964 | $4,870 |
| Net Cash Used in Operating Activities | $(6,335) | $(9,382) |
| Accumulated Deficit | $(117,539) | $(122,335) |
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $4.8 million in 2024 compared to a net loss of $6.5 million in 2023. This reversal was driven primarily by a non-cash gain of $14.8 million from a troubled debt restructuring with the European Investment Bank (EIB), where approximately $29 million of debt was converted into preferred shares.
- Revenue Generation: The company generated $658,000 in revenue in 2024, primarily from its CDMO business unit and a licensing agreement, marking the first time it has recognized revenue since inception.
- Expense Reduction: Operating expenses decreased by approximately $1.6 million year-over-year, largely due to a reduction in Marketing, General, and Administrative expenses (from $4.5 million to $2.5 million) resulting from cost-saving measures and reduced headcount.
- Liquidity: Cash and cash equivalents declined by approximately $2.9 million to $1.96 million, reflecting continued negative operating cash flows despite the net income reported.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The company's financial statements include a "substantial doubt" regarding its ability to continue as a going concern. Management states that current cash resources are insufficient to fund planned operations for at least one year beyond the filing date. Continued operations depend on obtaining additional financing.
- Cost-Saving Plan: The Board has approved a cost-saving plan involving headcount reductions (layoffs and non-paid leave) and the postponement of capital expenditures to extend the cash runway.
- Capital Requirements: The company requires substantial additional financing to fund R&D, clinical trials, and operations. It has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. to purchase up to $10 million of ADSs.
- Key Risks:
- Geopolitical: Operations in Israel are subject to risks from ongoing conflicts (Hamas, Hezbollah, Iran), which may disrupt operations, delay clinical trials, or impact employee availability due to reserve duty.
- Listing Compliance: The company previously faced delisting risks from Nasdaq regarding minimum bid price and stockholders' equity. It regained compliance in 2024 via a reverse split and the EIB debt-to-equity conversion.
- Development Risk: The company has no approved products. The lead candidate (anti-IL-17) is in pre-clinical stages, with Phase 1/2a trials expected to commence in late 2026. The COVID-19 program has been suspended.
- Acquisition Contingency: The company has an option to acquire Pincell srl (owner of PC111) but must secure $3 million or a specific grant by December 31, 2025, to exercise the option.
Important Facts for Investor Verification
- Debt Restructuring Impact: Verify the terms of the EIB loan conversion into preferred shares, specifically the redemption rights and voting privileges attached to the new preferred shares.
- Cash Runway: Confirm the sufficiency of the $1.96 million cash balance against the projected burn rate, given the "substantial doubt" disclosure.
- CDMO Viability: Assess the sustainability of the CDMO revenue stream ($658k in 2024) and the risk of impairment for the $9.2 million manufacturing facility if the CDMO unit fails to generate sufficient cash flow.
- Geopolitical Exposure: Evaluate the specific impact of the ongoing conflict in Israel on the company's ability to conduct pre-clinical studies and recruit staff.
- Equity Dilution: Monitor the execution of the $10 million SEPA and any future capital raises, which will likely result in significant dilution to existing shareholders.